INDIANAPOLIS (AP) — The drugmaker Eli Lilly and Co. said Tuesday that Sidney Taurel will retire as chief executive on March 31 after nearly a decade in the post and will step down as chairman of the board at the end of 2008. President and Chief Operating Officer John C. Lechleiter will take over as CEO on April 1.
Taurel, 58, has been Lilly's CEO since July 1998 and chairman since January 1999. He joined Lilly in 1971 as a marketing associate in Eli Lilly International, and over the next decades took on the London-based role of vice president of Lilly's European operations, and then moved to Indianapolis as president of Lilly International.
He later became an executive vice president of the company and president of the pharmaceutical division, and in 1996 was promoted to president and chief operating officer.
''I am grateful to have spent nearly 37 years with this great company, and deeply honored to have had the opportunity to lead it for the last 10,'' Taurel said in a statement. ''John has been preparing for his new role as my successor for several years, and 2008 is the right time for him to assume his place as the leader of the company.''
Lechleiter, 54, joined Lilly in 1979 and has served as president and COO since October 2005. He will continue as president besides his new role of CEO.
Earlier this month, Lilly issued a 2008 profit forecast above analyst expectations, predicting strong sales of antidepressant Cymbalta, erectile dysfunction treatment Cialis and diabetes drug Byetta. Lilly has said it plans to launch six new drugs or new formulations of existing drugs by 2011.
It also aims to have 10 drug compounds in late-stage clinical testing by 2011 and wants to launch two new compounds per year beginning in 2011, increasing to three per year by 2014. The forecast has been a boon to Lilly's shares, as most major pharmaceutical stocks have fallen as investors become apprehensive about expiring patents on blockbuster drugs which have driven profits for years.